
Guide to National Tenders for the Purchase of Clotting Factor Concentrates
This guide explains how a national procurement system of factor concentrates can help to ensure that people with bleeding disorders
Year: 2025
Language: English
Author(s): World Federation of Hemophilia
Format: Video
The World Federation of Hemophilia invited representatives from its national member organizations, national governments, healthcare providers, industry partners, and other patient advocacy and scientific organizations from the global bleeding disorders community to an informational webinar on the recent milestone revisions to the World Health Organization (WHO) Essential Medicines List (EML). The objectives of this webinar were to provide information on these critical changes to WHO EML brining it more up-to-date with the international clinical guidelines for hemophilia and von Willebrand Disease, the advocacy carried out by the WFH in collaboration with key partners and stakeholders from the bleeding disorders community, and what does this mean in practice for our community. During the webinar participants heard from WFH President, Cesar Garrido, WFH Vice President Medical, Glenn Pierce, MD, PhD and Brian O’Mahony, Chief Executive, Irish Haemophilia Society, followed by a Q&A session.
Date recorded: October 17th, 2025.
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.

This guide explains how a national procurement system of factor concentrates can help to ensure that people with bleeding disorders

A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia

A description of the mechanism of action of fibrinolytic inhibitors and their use in the treatment of inherited bleeding disorders

This report reviews the spectrum of indications of desmopressin in the treatment of bleeding disorders.

A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia

Presents data on the reported use of factor IX (FIX) per country. FIX use varies considerably, even among the wealthiest